Table 1.

Characteristics of the patients.

		Frequency (n)	Percentage (%)
Characteristics (n = 105)
Age, mean (SD)	49.7 (23.2)
Sex	Male	60	57.1
	Female	45	42.9
Comorbidities
Chronic kidney disease	NA	11	10.5
	No	93	88.6
	Yes	1	0.9
HIV	NA	11	10.5
	No	93	88.6
	Yes	1	0.9
Diabetes	NA	49	46.7
	No	39	37.1
	Yes	17	16.2
Hypertension	NA	46	43.8
	No	33	31.4
	Yes	26	24.8
Dyslipidemia	NA	11	10.5
	No	91	86.7
	Yes	3	2.8
Asthma	NA	11	10.5
	No	92	87.6
	Yes	2	1.9
Migraine	NA	11	10.5
	No	93	88.6
	Yes	1	0.9
Hyperuricemia	NA	11	10.5
	No	93	88.6
	Yes	1	0.9
Obesity	NA	11	10.5
	No	93	88.6
	Yes	1	0.9
Heart failure	NA	59	56.2
	No	41	39
	Yes	5	4.8
Thyroid dysfunction	NA	11	10.5
	No	93	88.6
	Yes	1	0.9
Cancer	NA	11	10.5
	No	93	88.6
	Yes	1	0.9
Poliomyelitis	NA	11	10.5
	No	93	88.6
	Yes	1	0.9
Stroke	NA	11	10.5
	No	93	88.6
	Yes	1	0.9
Obstructive sleep apnea	NA	11	10.5
	No	93	88.6
	Yes	1	0.9
Meniere’s disease	NA	11	10.5
	No	93	88.6
	Yes	1	0.9
Vaccines
Type of given vaccine	NA	1	0.9
	Moderna	6	5.7
	Pfizer	49	46.7
	AstraZeneca	16	15.3
	Sinovac Biotech	22	21
	Johnson & Johnson	2	1.9
	Sputnik V	7	6.7
	Vector based vaccine	1	0.9
	COVAXIN	1	0.9
Doses
Dosage resulted in the symptoms	NA	57	54.3
	1	37	35.2
	2	11	10.5
Diagnostic tools, treatments, and prognosis (n = 52)
Diagnostic tools
Physical examination	NA	1	1.9
	No	2	3.8
	Yes	49	94.2
CT	No	44	84.6
	Yes	8	15.4
MRI	No	23	44.2
	Yes	29	55.8
EMG	No	46	88.5
	Yes	6	11.5
Nerve conduction	No	47	90.4
	Yes	5	9.6
Lumbar puncture	No	31	59.6
	Yes	21	40.4
Electrophoresis	NA	1	1.9
	No	39	75
	Yes	12	23.1
Treatments
Prednisone	NA	11	21.2
	No	21	40.4
	Yes	20	38.5
Methylprednisolone	NA	11	21.2
	No	38	73.1
	Yes	3	5.8
Deflazacort	NA	11	21.2
	No	40	76.9
	Yes	1	1.9
IVIG	NA	11	21.2
	No	27	51.9
	Yes	14	26.9
Anti-viral	NA	11	21.2
	No	34	65.4
	Yes	7	13.5
Plasma exchange	NA	11	21.2
	No	40	76.9
	Yes	1	1.9
Follow-up time, mean (SD)	30.19 (72.55)
Outcome
The affected side of the face	Unilateral	36	69.2
	Bilateral	16	30.8
Time of symptoms onset (days), mean (SD)	11.6 (11.13)
Prognosis	NA	12	21.2
	No response	5	9.6
	Partial response	13	25
	Complete response	23	44.2
Overall prognosis	NA	12	21.2
	Not Recovered	5	9.6
	Recovered	36	69.2